Literature DB >> 22748605

MicroRNAs and atherosclerosis: new actors for an old movie.

D Santovito1, A Mezzetti, F Cipollone.   

Abstract

To date, cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality worldwide. MicroRNAs (miRNAs) are endogenous, short, non-coding RNA sequences able to regulate gene expression principally at the post-transcriptional level. Initially, they were thought to be involved only in developmental timing of worms. Their involvement in human biology was recently discovered and many studies have been performed to demonstrate the role of miRNA in human cancer. Since the first observation in 2005 of their implication in cardiac biology, many studies have demonstrated their role in the genetic modulation of cardiovascular development and in cardiovascular diseases such as cardial remodeling and heart failure, cardiac arrhythmias, cardiac ischaemia, cardiac fibrosis, atherosclerosis and stroke. Thus, the aim of this review is to describe the role of miRNA in atherosclerosis development and evolution and to individuate their role as potential therapeutic target.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748605     DOI: 10.1016/j.numecd.2012.03.007

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  23 in total

1.  Circulating and renal vein levels of microRNAs in patients with renal artery stenosis.

Authors:  Moo Yong Park; Sandra M Herrmann; Ahmed Saad; Robert Jay Widmer; Hui Tang; Xiang-Yang Zhu; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2014-10-31       Impact factor: 5.992

Review 2.  Angiogenesis-regulating microRNAs and Ischemic Stroke.

Authors:  Ke-Jie Yin; Milton Hamblin; Y Eugene Chen
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

Review 3.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

4.  Lactobacillus acidophilus Increases the Anti-apoptotic Micro RNA-21 and Decreases the Pro-inflammatory Micro RNA-155 in the LPS-Treated Human Endothelial Cells.

Authors:  Mehdi Kalani; Hossein Hodjati; Mahdi Sajedi Khanian; Mehrnoosh Doroudchi
Journal:  Probiotics Antimicrob Proteins       Date:  2016-06       Impact factor: 4.609

5.  Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.

Authors:  Hailing Liu; Yan Wang; Xin Li; Yan-jun Zhang; Jie Li; Yi-qiong Zheng; Mei Liu; Xin Song; Xi-ru Li
Journal:  Tumour Biol       Date:  2013-02-22

6.  Differential miRNA expression profiles between the first and third trimester human placentas.

Authors:  Yang Gu; Jingxia Sun; Lynn J Groome; Yuping Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-26       Impact factor: 4.310

Review 7.  From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis.

Authors:  D D'Ardes; F Santilli; M T Guagnano; M Bucci; F Cipollone
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-01-10

8.  Association analysis of USF1 gene polymorphisms and total unstable carotid plaque area in atherosclerotic stroke patients.

Authors:  Rui-Min Wang; Zhi-Zhong Liu; Yan-Hua Gong; Li-Jun Chen; Qian Jia; Ya-Jie Wang; Fang Fang; Hong Lv; Guo-Jun Zhang; Xi-Xiong Kang
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

9.  MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms.

Authors:  Claudia Goettsch; Joshua D Hutcheson; Elena Aikawa
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

10.  Circulating microRNAs as Novel Biomarkers for Atherosclerosis.

Authors:  Seda Gulec Yilmaz; Selim Isbir; Atike Tekeli Kunt; Turgay Isbir
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.